glp-1 cardiovascular outcomes 2025 news Novo cuts prices 70%, but semaglutide revenue could grow in 2026 Cardiovascular Outcomes in Diabetes: New
Description
Thus, there remains an urgent need to address these drug shortages through several different strategies
Resistance training gives your body a reason to hold on to muscle while you are in a calorie deficit
As compounded GLP-1s are not a standard, FDA-approved dosage, they havent gone through the same clinical trials
Who should consider getting off GLP-1 medications Not everyone should stop
Patients with T2DM are also at an increased risk of myocardial infarction, stroke, and other major adverse cardiac events (MACE) [11]
[2] However, there have been limited post-marketing reports of muscle cramps, including in the legs, during treatment, though a direct causal relationship has not been established
